No Data
No Data
Huapont Life Sciences (002004.SZ): The specific timetable for Hanjiang Pharmaceutical's listing has not yet been determined.
On July 16th, Huapont Life Sciences (002004.SZ) stated on the investor interaction platform that Hanjiang Pharmaceutical is a subsidiary of the company, mainly engaged in the research and development, production, and sales of pharmaceutical active ingredients and intermediates, covering products such as corticosteroids, anthelmintic, respiratory system, and digestive system, and has established long-term cooperation relationships with internationally renowned pharmaceutical companies such as Abbott Laboratories, Johnson & Johnson, Eli Lilly and Co, and Merck. The specific timetable for the listing of Hanjiang Pharmaceuticals has not yet been determined, but Hanjiang Pharmaceuticals has the possibility of being listed based on its business and operating performance, and the specific situation should be based on the company's announcement information.
Huapont Life Sciences (002004.SZ): As of July 10th, the number of shareholders in the company is 79,950.
On July 16th, Gelunhui reported that as of July 10, 2024, the number of shareholders in Huapont Life Sciences (002004.SZ) was 79950.
Huapont Life Sciences (002004.SZ): cumulative repurchase of 0.29% of shares.
Huapont Life Sciences (002004.SZ) announced that as of June 30, 2024, the company had accumulated a repurchase of 5,785,808 shares through centralized trading, accounting for 0.29% of the company's current total share capital. The highest fill price was 4.65 yuan/share, the lowest fill price was 3.88 yuan/share, and the total amount paid was 24,966,124.13 yuan (excluding transaction fees). The repurchase complies with the company's stock buyback plan and relevant laws and regulations.
Huapont life sciences (002004.SZ): Beijing Huasheng Rehabilitation Hospital outpatient service increased by 31% year-on-year.
On June 21st, Galon Healthcare reported on the investor feedback platform that Beijing Shengkang Rehabilitation Hospital is a tertiary rehabilitation specialty hospital. Since officially launching medical insurance services in September 2022, the number of patients has been steadily increasing and the operation is in good condition. In the first quarter of 2024, the number of outpatients (emergency) received increased by about 31% compared with the same period last year, and the bed occupancy rate is close to 90%. The Chongqing Songshan Hospital, which was constructed by the company, is a tertiary comprehensive hospital. Since opening, it has maintained high-speed development. The number of outpatient (emergency) service visits in the first quarter of 2024 increased compared with the same period last year.
Kaiceng New Materials (301069.SZ): Shareholder Huapont Life Sciences is reducing its shareholding of 1 million "Kaiceng Convertible Bonds".
Gelonghui, June 19丨Kaisheng New Materials (301069.SZ) announced that the company recently received a notice from the controlling shareholder Huabang Health and learned that it reduced its total holdings of “Kaisheng Convertible Bonds” by 1,000,000 shares through bulk transactions between June 11, 2024 and June 18, 2024, accounting for 15.38% of the total amount issued. Previously, according to the China Securities Regulatory Commission's “Approval for Shandong Kaisheng New Materials Co., Ltd. to Register the Issuance of Convertible Corporate Bonds to Unspecified Targets” (Securities Regulatory License [2023] No. 1893), Shandong Kaisheng New Materials Co., Ltd. has
As of June 10, 2024, the shareholder number of Huapont Life Sciences (002004.SZ) was 79,571 households.
Huapont Life Sciences (002004.SZ) stated on the investor interaction platform on June 13th that the company's current operation is normal. As of June 10th, 2024, the number of shareholders of the company was 79,571.
No Data